Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

Dow Jones04-10 19:28

1128 GMT - Any comments from Roche Holding about its long-term prospects will be the main focal point when the group provides an update on its diagnostics business next month, UBS analysts say in a research note. Recent clinical-trial results for drug candidates giredestrant in breast cancer and fenebrutinib in multiple sclerosis, as well as for Gazyva in systemic lupus, mean investors will want to get an update from CEO Thomas Schinecker at the event scheduled for May 12, UBS says. "We expect that Roche management will provide some indicative targets for group top-line growth, and potentially margins, relative to consensus expectations," the analysts say. "We do not expect formal midterm financial guidance as the company has historically only provided 'guidance' for a single year out." Shares rise 0.8%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 07:28 ET (11:28 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626194035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626194035","market":"hk","top_or_hot":-1,"title":"Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1128 GMT - Any comments from Roche Holding about its long-term prospects will be the main focal point when the group provides an update on its diagnostics business next month, UBS analysts say in a research note. Recent clinical-trial results for drug candidates giredestrant in breast cancer and fenebrutinib in multiple sclerosis, as well as for Gazyva in systemic lupus, mean investors will want to get an update from CEO Thomas Schinecker at the event scheduled for May 12, UBS says. \"We expect that Roche management will provide some indicative targets for group top-line growth, and potentially margins, relative to consensus expectations,\" the analysts say. \"We do not expect formal midterm financial guidance as the company has historically only provided 'guidance' for a single year out.\" Shares rise 0.8%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 19:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1128 GMT - Any comments from Roche Holding about its long-term prospects will be the main focal point when the group provides an update on its diagnostics business next month, UBS analysts say in a research note. Recent clinical-trial results for drug candidates giredestrant in breast cancer and fenebrutinib in multiple sclerosis, as well as for Gazyva in systemic lupus, mean investors will want to get an update from CEO Thomas Schinecker at the event scheduled for May 12, UBS says. \"We expect that Roche management will provide some indicative targets for group top-line growth, and potentially margins, relative to consensus expectations,\" the analysts say. \"We do not expect formal midterm financial guidance as the company has historically only provided 'guidance' for a single year out.\" Shares rise 0.8%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626194035","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626194035","pubTimestamp":1775820480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1128 GMT - Any comments from Roche Holding about its long-term prospects will be the main focal point when the group provides an update on its diagnostics business next month, UBS analysts say in a research note. Recent clinical-trial results for drug candidates giredestrant in breast cancer and fenebrutinib in multiple sclerosis, as well as for Gazyva in systemic lupus, mean investors will want to get an update from CEO Thomas Schinecker at the event scheduled for May 12, UBS says. \"We expect that Roche management will provide some indicative targets for group top-line growth, and potentially margins, relative to consensus expectations,\" the analysts say. \"We do not expect formal midterm financial guidance as the company has historically only provided 'guidance' for a single year out.\" Shares rise 0.8%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","03165":"华夏欧优股对冲","RHHBY":"罗氏控股"},"translate_title":"罗氏的长期前景将在诊断活动中成为焦点——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"1128 GMT - Any comments from Roche Holding about its long-term prospects will be the main focal point when the group provides an update on its diagnostics business next month, UBS analysts say in a research note. Recent clinical-trial results for drug candidates giredestrant in breast cancer and fenebrutinib in multiple sclerosis, as well as for Gazyva in systemic lupus, mean investors will want to get an update from CEO Thomas Schinecker at the event scheduled for May 12, UBS says. \"We expect that Roche management will provide some indicative targets for group top-line growth, and potentially margins, relative to consensus expectations,\" the analysts say. \"We do not expect formal midterm financial guidance as the company has historically only provided 'guidance' for a single year out.\" Shares rise 0.8%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 07:28 ET (11:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626194035","isCrawlerRequest":true}